Antisense Oligonucleotides Market is driven by Growing Adoption of Personalized Medicine

Antisense oligonucleotides are short DNA or RNA fragments that bind to target mRNA to disrupt gene expression or function. They have applications in drug discovery and development, functional genomics, and agriculture and biotechnology. Antisense oligos help modulate gene expression by interacting with target RNA through Watson-Crick base pairing. This technology has shown promise for the treatment of neurodegenerative disorders, infectious diseases, cancer, and genetic disorders.

The Global Antisense Oligonucleotides Market is estimated to be valued at US$3.1 billion in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period 2024-2032.

Key Takeaways

The growing demand for effective therapeutics for the treatment of neurological disorders and cancer is driving market growth. Antisense Oligonucleotides Market Size provide targeted inhibition of disease-causing genes without affecting other healthy processes in the body.

Leading players are expanding their presence in major markets to cater to the growing demand. For instance, Ionis Pharmaceuticals collaborates with pharmaceutical companies like Biogen, Novartis, and Roche to develop and commercialize antisense drugs globally. Increasing R&D investments are also helping to develop antisense oligonucleotides for various new therapeutic areas.

Get more insights on- Antisense Oligonucleotides Market

Explore More Related Article On- Tuberculosis Vaccine